Phase 1 Safety and Immunogenicity Trial of Recombinant Lactococcus Lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine in Healthy Females
Molecular Therapy - Methods and Clinical Development - United States
doi 10.1016/j.omtm.2019.08.005
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Elsevier BV